Breast Cancer

, Volume 25, Issue 6, pp 742–752 | Cite as

MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1

  • Xiang Peng
  • Bin Yan
  • Yufeng ShenEmail author
Original Article



MiRNAs regulate a variety of biological processes, such as cell proliferation and apoptosis and play critical roles in cancer progression. Accumulating studies have demonstrated that miR-1301-3p could regulate the development and progression of multiple cancers, but its biological behaviors in breast cancer (BC) are still elusive.


The expression of miR-1301-3p was determined in BC tissues and cell lines using quantitative real-time PCR analysis. The effects of miR-1301-3p on BC cell growth, proliferation, cell cycle distribution, and apoptosis were also explored in vitro using MTT, colony formation and Flow cytometry assays. The potential target gene of miR-1301-3p was determined by dual-luciferase reporter assay and verified by quantitative real-time PCR and western blot analysis.


We found the expression of miR-1301-3p was observably significantly down-regulated in BC tissues and cell lines. MiR-1301-3p expression in BC tissues was significantly associated with tumor size and clinical stage. Gain-of-function assays demonstrated that miR-1301-3p inhibited the cell growth and proliferation in breast cancer cell lines, MCF-7 and T-47D. Moreover, up-regulation of miR-1301-3p induced cell cycle G0/G1 phase arrest and apoptosis. Mechanistically, up-regulation of miR-1301-3p reduced the expression of CDK4, Cyclin D1, Bcl-2, but elevated the expression of p21, Bad and Bax. ICT1 was confirmed as a direct target of miR-1301-3p. Furthermore, ICT1 overexpression could partially reverse the effects of miR-1301-3p on BC cell proliferation, cell cycle progression and apoptosis.


Our observations suggested that miR-1301-3p inhibits cell proliferation via inducing cell cycle arrest and apoptosis through targeting ICT1, and might be a therapeutic target for BC.


Breast cancer MiR-1301-3p Cell proliferation Cell cycle Apoptosis ICT1 


Compliance with ethical standards

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


  1. 1.
    Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, et al. Cancer statistics: breast cancer in situ. CA Cancer J Clin. 2015;65:481–95.CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRefGoogle Scholar
  3. 3.
    DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439–48.CrossRefGoogle Scholar
  4. 4.
    Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526:131–5.CrossRefGoogle Scholar
  5. 5.
    Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer–a brief overview. Adv Biol Regul. 2015;57:1–9.CrossRefGoogle Scholar
  6. 6.
    Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.CrossRefGoogle Scholar
  7. 7.
    Betel D, Wilson M, Gabow A, Marks DS, Sander C. The resource: targets and expression. Nucleic Acids Res. 2008;36:D149-53.PubMedGoogle Scholar
  8. 8.
    Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med. 2006;79:131–40.PubMedGoogle Scholar
  9. 9.
    Arcila ML, Betizeau M, Cambronne XA, Guzman E, Doerflinger N, Bouhallier F, et al. Novel primate miRNAs coevolved with ancient target genes in germinal zone-specific expression patterns. Neuron. 2014;81:1255–62.CrossRefGoogle Scholar
  10. 10.
    Zhi T, Jiang K, Zhang C, Xu X, Wu W, Nie E, et al. MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras. Am J Cancer Res. 2017;7:982–98.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Song XL, Huang B, Zhou BW, Wang C, Liao ZW, Yu Y, et al. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3beta. Biomed Pharmacother. 2018;99:369–74.CrossRefGoogle Scholar
  12. 12.
    Richter R, Rorbach J, Pajak A, Smith PM, Wessels HJ, Huynen MA, et al. A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome. EMBO J. 2010;29:1116–25.CrossRefGoogle Scholar
  13. 13.
    Handa Y, Hikawa Y, Tochio N, Kogure H, Inoue M, Koshiba S, et al. Solution structure of the catalytic domain of the mitochondrial protein ICT1 that is essential for cell vitality. J Mol Biol. 2010;404:260–73.CrossRefGoogle Scholar
  14. 14.
    Lao X, Feng Q, He G, Ji M, Zhu D, Xu P, et al. Immature colon carcinoma transcript-1 (ICT1) expression correlates with unfavorable prognosis and survival in patients with colorectal cancer. Ann Surg Oncol. 2016;23:3924–33.CrossRefGoogle Scholar
  15. 15.
    Wang Z, Xu D, Gao Y, Liu Y, Ren J, Yao Y, et al. Immature colon carcinoma transcript 1 is essential for prostate cancer cell viability and proliferation. Cancer Biother Radiopharm. 2015;30:278–84.CrossRefGoogle Scholar
  16. 16.
    Wang C, Liang C, Feng W, Xia X, Chen F, Qiao E, et al. ICT1 knockdown inhibits breast cancer cell growth via induction of cell cycle arrest and apoptosis. Int J Mol Med. 2017;39:1037–45.CrossRefGoogle Scholar
  17. 17.
    Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.CrossRefGoogle Scholar
  18. 18.
    Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefGoogle Scholar
  19. 19.
    Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRefGoogle Scholar
  20. 20.
    Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–93.CrossRefGoogle Scholar
  21. 21.
    Kreis NN, Louwen F, Yuan J. Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene. 2015;34:1758–67.CrossRefGoogle Scholar
  22. 22.
    Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene. 1998;16:217–25.CrossRefGoogle Scholar
  23. 23.
    Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1999;5:4152–7.PubMedGoogle Scholar
  24. 24.
    Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–42.CrossRefGoogle Scholar
  25. 25.
    Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer’s disease. Brain Res. 1998;780:260–9.CrossRefGoogle Scholar
  26. 26.
    Grosse L, Wurm CA, Bruser C, Neumann D, Jans DC, Jakobs S. Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. EMBO J. 2016;35:402–13.CrossRefGoogle Scholar
  27. 27.
    Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol. 2000;20:453–61.CrossRefGoogle Scholar
  28. 28.
    Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast Cancer. 2016;19:252–60.CrossRefGoogle Scholar
  29. 29.
    Wei C, Luo Q, Sun X, Li D, Song H, Li X, et al. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol. 2015;8:7729–39.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Huang P, Ye B, Yang Y, Shi J, Zhao H. MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. Tumour Biol. 2015;36:3381–7.CrossRefGoogle Scholar
  31. 31.
    Chrzanowska-Lightowlers ZM, Lightowlers RN. Response to “ribosome rescue and translation termination at non-standard stop codons by ICT1 in mammalian mitochondria”. PLoS Genet. 2015;11:e1005227.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2018

Authors and Affiliations

  1. 1.Department of SurgeryQingpu Branch of Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina

Personalised recommendations